Erythematous candidiasis presents as red macular lesions that evoke a burning sensation. These lesions occur on the posterior hard palate, buccal mucosa, and the dorsum of the tongue. 13 ...

Oravig will be available in a 50mg dosage strength as a flavorless, odorless buccal tablet. It is expected to be made available in the third quarter of 2010. For more information call (201) 802 ...

Dara BioSciences is the new marketer of the only orally dissolving buccal tablet approved for oral thrush, which occurs when the Candida albicans fungus grows in the lining of the mouth. ...

Lichenoid reaction in buccal mucosa, reaction to amalgam contact Full size image White lesions of LP are often asymptomatic, but there may be soreness if there are atrophic areas or erosions.

SO-1105 is an antifungal agent, administered as a muco-adhesive buccal tablet for the treatment of oropharyngeal candidiasis in immunocompromised patients. SO- 1105 has the potential to become the ...

ORAVIG (miconazole) 50mg buccal tablets by Strativa Strativa has made available Oravig (miconazole buccal tablets) for the treatment of oropharyngeal candidiasis (OPC) in patients ≥16 years of age.

Loramyc is an antifungal agent, administered as a muco-adhesive buccal tablet for the treatment of oropharyngeal candidiasis in immunocompromised patients. BioAlliance received its first Loramyc ...

The FDA has approved Oravig buccal tablets for the treatment of oropharyngeal candidiasis in adults and childen aged 16 years and older. Menu SECTIONS. News; ...

Pevion Biotech AG's Therapeutic Candida Vaccine Shows Robust Systemic and Mucosal Immunogenicity, While Epidemiological Survey Confirms Excellent Market Potential BERN, Switzerland, October 11, 2011 ...